tirzepatide heart racing Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Failure: SUMMIT CMR Substudy Effects of Tirzepatide on the

Therefore, treatment capable of reducing synovial inflammation and slowing down cartilage destruction should have the essential characteristics of disease-modifying OA drugs (DMOADs)

The newly developed GLPMnO 2 nanozyme integrates intrinsic catalase (CAT) and superoxide dismutase (SOD)-mimetic activities with selective hepatic accumulation and real-time MRI contrast capability, thereby enabling synergistic antioxidant intervention and non-invasive monitoringsignificantly amplifying its antifibrotic efficacy in vivo (Jiang et al., 2021

A.GhoshP.PesapaneA.TaktazF.PuocciA.FranzeseM.et al (2024)

Wang W, Bain SC, Bian F, Chen R, Gabery S, Huang S, Jensen TB, Luo B, Yuan G, Ning G